Their non-peptide formulation also addresses several limitations associated with injectable biologics, making them an attractive alternative for the long-term management of type 2 diabetes and obesity
Their primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels with a low risk of hypoglycaemia when used alone (though risk increases when combined with insulin or sulfonylureas) Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake These combined effects result in improved glycaemic control for people with diabetes and significant weight loss
Daily sunscreen can help protect the glow and reduce the return of tanning
Over the last few years, novel non-steroidal MRAs such as finerenone have been developed that demonstrate greater mineralocorticoid receptor selectivity and other pharmacokinetic differences compared with steroidal MRAs [67]
Inhibition of protein kinase CK2 by flavonoids and tyrphostins
Studies show DSIP modulates the hypothalamic-pituitary-adrenal axis, reducing cortisol and stress responses